Clinical Trials
22 trialsNCT07518147 2026-06-04
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06346392 2026-05-27
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Active not recruiting
NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
NCT07364422 2026-01-23
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Onconic Therapeutics Inc.
Phase 1/2 Not yet recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT06769425 2025-06-24
HS-10502
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04581473 2025-06-05
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT05427383 2023-12-19
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
Phase 2/3 Recruiting
NCT04486651 2021-01-28
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT01084330 2020-12-10
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer
Novartis
Phase 2 Completed
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT01040312 2019-05-23
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
Daiichi Sankyo
Completed
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT01813253 2018-03-26
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
Kuhnil Pharmaceutical Co., Ltd.
Phase 3 Terminated
NCT01070290 2014-01-07
A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Withdrawn
NCT00813072 2012-03-02
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PharmaEngine
Phase 2 Completed
NCT00044785 2005-06-24
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Wellstat Therapeutics
Phase 1 Terminated